BridgeMD
Multicenter clinical trial on the effectiveness and safety of outpatient treatment of acute uncomplicated diverticulitis without antibiotics versus antibiotic treatment. ADIANA Trial.
EU CTIS ID: 2025-523121-17-00
What this study is testing
To evaluate the effectiveness and safety of outpatient treatment without antibiotics compared to outpatient treatment with antibiotics in patients with uncomplicated acute diverticulitis.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients over 18 years of age with a clinical and radiological diagnosis of uncomplicated acute diverticulitis of the sigmoid colon or descending colon (left-sided AD).
- Radiological diagnosis of acute uncomplicated diverticulitis by CT scan (modified Hinchey classification 0-Ia).
- First episode or previous history of AD (both complicated and uncomplicated, and ≥6 months having elapsed since the last episode to the current clinic visit).
- Signing of the informed consent form to participate in the study
You likely can't join if
- Age >70 years old
- Patients who are candidates for hospitalization and/or intravenous antibiotic therapy (at diagnosis): Repeated vomiting or oral intolerance, need for intravenous fluid therapy and/or close monitoring, temperature >38°C, deterioration of general condition, and/or clinical suspicion of sepsis.
- Significant or decompensated comorbidity (ASA classification IV).
- Immunocompromised patients: Hematological causes, HIV with low CD4+ levels, immunosuppressive treatment, prolonged treatment with corticosteroids, chemotherapy, transplant or splenectomy patients, predisposing genetic disorders (severe combined immunodeficiency, etc.).
- Oral or intravenous antibiotic therapy in the 2 weeks prior to the onset of symptoms, for another cause.
- Pregnancy
See the full eligibility criteria
- Patients over 18 years of age with a clinical and radiological diagnosis of uncomplicated acute diverticulitis of the sigmoid colon or descending colon (left-sided AD).
- Radiological diagnosis of acute uncomplicated diverticulitis by CT scan (modified Hinchey classification 0-Ia).
- First episode or previous history of AD (both complicated and uncomplicated, and ≥6 months having elapsed since the last episode to the current clinic visit).
- Signing of the informed consent form to participate in the study
- Age >70 years old
- Patients who are candidates for hospitalization and/or intravenous antibiotic therapy (at diagnosis): Repeated vomiting or oral intolerance, need for intravenous fluid therapy and/or close monitoring, temperature >38°C, deterioration of general condition, and/or clinical suspicion of sepsis.
- Significant or decompensated comorbidity (ASA classification IV).
- Immunocompromised patients: Hematological causes, HIV with low CD4+ levels, immunosuppressive treatment, prolonged treatment with corticosteroids, chemotherapy, transplant or splenectomy patients, predisposing genetic disorders (severe combined immunodeficiency, etc.).
- Oral or intravenous antibiotic therapy in the 2 weeks prior to the onset of symptoms, for another cause.
- Pregnancy
- Inflammatory bowel disease (Crohn's disease, ulcerative colitis).
- Lack of social support that makes outpatient treatment impossible.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.